Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: A randomized trial of the European organization for research and treatment of cancer melanoma cooperative group

Journal of Clinical Oncology

Volumn 15, Issue 7, 1997, Pages 2579-2588

  Keilholz, Ulrich ^a   Goey, Swan Hoo ^a   Punt, Cornelis J A ^a   Proebstle, Thomas M ^a   Salzmann, Ralph ^a   Scheibenbogen, Carmen ^a   Schadendorf, Dirk ^a   Liénard, Danielle ^a   Enk, Alexander ^a   Dummer, Reinhard ^a   Hantich, Birgit ^a   Geueke, Anne Marie ^a   Eggermont, Alexander M M ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2 INTERFERON; CISPLATIN; INTERLEUKIN 2; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT INTERLEUKIN 2;

ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EUROPE; FEVER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MELANOMA; NEPHROTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN METASTASIS; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0342894822     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.7.2579     Document Type: Article

References (31)

1. Kirkwood JM: Systemic therapy of melanoma. Curr Opin Oncol 6:204-211, 199 4
2. Legha S: Current therapy for malignant melanoma. Semin Oncol 16:34-44, 1989
3. Lakhani S, Selby P, Bliss JM, et al: Chemotherapy for malignant melanoma: Combinations and high doses produce more responses without survival benefit. Br J Cancer 61:330-334, 1990
4. West WH, Tauer KW, Yanelli JR, et al: Constant infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316:898-905, 1987
5. Rosenberg SA, Lotze MT, Yang JC, et al: Experience with the use of high dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 210:474-485, 1989
6. Parkinson DR, Fisher RI, Rayner AA, et al: IL-2 therapy in patients with metastatic malignant melanoma: A phase II study. J Clin Oncol 8:1650-1656, 1990
7. Whitehead RP, Kopecky KJ, Samson MK, et al: Phase II study of intravenous recombinant IL-2 in advanced malignant melanoma: Southwest Oncology Group study. J Natl Cancer Inst 83:1250-1251, 1991
8. Kirkwood JM: Studies of interferons in the therapy of melanoma. Semin Oncol 18:83-90, 1991
9. Rosenberg SA, Lotze MT, Yang JC, et al: Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol 7:1863-1874, 1989
10. Lee KH, Talpaz M, Rothberg JM, et al: Concomitant administration of recombinant human interleukin-2 and recombinant interferona 2A in cancer patients: A phase 1 study. J Clin Oncol 7:1726-1732, 1989
11. Keilholz U, Scheibenbogen C, Tilgen W, et al: Interferon-α and interleukin-2 in the treatment of malignant melanoma: A comparison of two phase II trials. Cancer 72:607-614, 1993
12. Kruit WH, Punt CJA, Goey SH, et al: Dose-efficacy study of two schedules of high-dose bolus administration of interleukin-2 and alpha-interferon in patients with metastatic melanoma Br J Cancer 74:951-955, 1996
13. Stoter G, Aamdal S, Rodenhuis S, et al: Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma: A multicenter phase II study. J Clin Oncol 9:1687-1691, 1991
14. Flaherty LE, Robinson W, Redman B, et al: A phase II study of dacarbazine and cisplatin in combination with outpatient administered IL-2 in metastatic malignant melanoma. Cancer 71:3520-3525, 1993
15. Dummer R, Gore ME, Hancock BW, et al: A multi-center phase II clinical trial using dacarbazine and continuous infusion of interleukin-2 in metastatic melanoma: Clinical data and immunomonitoring. Cancer 75:1038-1044, 1995
16. Richards JM, Mehta N, Ramming K, et al: Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol 10:1338-1343, 1992
17. Khayat D, Antoine E, Rixe O, et al: Chemoimmunotherapy of metastatic malignant melanoma. The Salpétrière Hospital experience. Eur J Cancer 29:2-5, 1993 (suppl 5)
18. Buzaid AC, Legha SS: Combination of chemotherapy with interleukin-2 and interferon-alfa for the treatment of advanced melanoma. Semin Oncol 6:23-28, 1994 (suppl 14)
19. Atkins MB, O'Boyle KR, Sosman JA, et al: Multiinstitutional phase II trial of intensive combination chemotherapy for metastatic melanoma. J Clin Oncol 12:1553-1560, 1994
20. Kruit WH, Punt KJ, Goey SH, et al: Cardiotoxicity as a dose-limiting factor in a schedule of high dose bolus therapy with interleukin-2 and alpha-interferon. An unexpectedly frequent complication. Cancer 74:2850-2856, 1994
21. Marincola FM, White DE, Wise AP, et al: Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer. J Clin Oncol 13:1110-1122, 1995
22. Keilholz U, Scheibenbogen C, Möhler T, et al: Addition of dacarbazine or cisplatin to IFNα/IL-2 in metastatic melanoma: Toxicity and immunological effects. Melanoma Res 5:283-287, 1995
23. Redman BG, Flaherty L, Chou TH, et al: Sequential dacarbazine/cisplatin and interleukin-2 in metastatic melanoma: Immunological effects of therapy. J Immunother 10:147-151, 1991
24. Lichtenstein AK, Pende D: Enhancement of natural killer cytotoxicity by diamminedichloroplatinum in vivo and in vitro. Cancer Res 46:639-644, 1986
25. World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland, WHO
26. Keilholz U: Chemo-immunotherapy of melanoma: Is it time for phase III trials? Cancer 75:905-907, 1995 (editorial)
27. Keilholz U, Scheibenbogen C, Sommer M, et al: Prognostic factors for response and survival in patients with metastatic melanoma receiving immunotherapy. Melanoma Res 6:173-178, 1996
28. Keilholz U, Scheibenbogen C, Stoelben E, et al: Immunotherapy of metastatic melanoma with IFNα and IL-2: Pattern of progression in responders and patients with stable disease without or with resection of residual lesions. Eur J Cancer 30A:955-958, 1994
29. Ahman DL, Creagan ET, Hahn RG, et al: Complete responses and long-term survivals after systemic chemotherapy for patients with advanced malignant melanoma. Cancer 63:224-227, 1989
30. Creagan ET, Schaid DJ, Ahmann DL, et al: Disseminated malignant melanoma and recombinant interferon: Analysis of seven consecutive phase II investigations. J Invest Dermatol 95:188S-192S, 1990
31. Sirott MN, Bajorin DF, Wong GJC, et al: Prognostic factors in patients with metastatic melanoma: A multivariate analysis. Cancer 72:3091-3098, 1993